1. Home
  2. PMAX vs EDSA Comparison

PMAX vs EDSA Comparison

Compare PMAX & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Powell Max Limited

PMAX

Powell Max Limited

HOLD

Current Price

$2.04

Market Cap

6.4M

Sector

N/A

ML Signal

HOLD

Logo Edesa Biotech Inc.

EDSA

Edesa Biotech Inc.

HOLD

Current Price

$3.68

Market Cap

7.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PMAX
EDSA
Founded
2019
2015
Country
Hong Kong
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4M
7.5M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
PMAX
EDSA
Price
$2.04
$3.68
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$13.00
AVG Volume (30 Days)
15.0K
3.7M
Earning Date
01-01-0001
05-22-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.23
$0.72
52 Week High
$5.20
$2.95

Technical Indicators

Market Signals
Indicator
PMAX
EDSA
Relative Strength Index (RSI) 36.26 85.14
Support Level $1.61 $2.01
Resistance Level $2.67 N/A
Average True Range (ATR) 0.16 0.42
MACD -0.05 0.25
Stochastic Oscillator 0.15 84.88

Price Performance

Historical Comparison
PMAX
EDSA

About PMAX Powell Max Limited

Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. All operations are carried in Hong Kong.

About EDSA Edesa Biotech Inc.

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

Share on Social Networks: